NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Elanco Animal Health Inc is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
Elanco Animal Health develops and distributes medicines and therapies for pets and farm animals across multiple countries. The company offers parasiticides, dermatology products and vaccines for companion animals, alongside health solutions for cattle, poultry, swine and sheep. Its offerings reach farmers, veterinarians, pet owners and distributors globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Elanco Animal Health Inc stock.
Overvalued: intrinsic value $15.17 per share, market price $23.49, margin of safety -54.8% (as of 2026-10-19).
Discounting its cash flows at 10.7% (average of 2 methods) values the shares at $15.17; the price of $23.49 is 55% above that value, and 70% of that value comes from beyond year five.
Leak Score: 24/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
18 more in this industry show a wider margin of safety.
ELAN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.7% (average of 2 methods) values the shares at $15.17; the price of $23.49 is 55% above that value, and 70% of that value comes from beyond year five.
$15.17 per share (as of the 2026-10-19 close), against a market price of $23.49. That is a margin of safety of -54.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
24 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.